Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hyoscine butyl bromide + lidocaine is a combination drug consisting of two active pharmaceutical ingredients: - **Hyoscine butyl bromide** (also known as scopolamine butylbromide or HBB) is an anticholinergic agent that acts primarily as a peripherally selective muscarinic receptor antagonist. It relaxes smooth muscle in the gastrointestinal and genitourinary tracts by blocking acetylcholine at muscarinic receptors, leading to spasmolytic and analgesic effects. It does not cross the blood-brain barrier due to its quaternary ammonium structure[1][2][6]. - **Lidocaine** is a local anesthetic of the amide type that works by blocking voltage-gated sodium channels on neuronal cell membranes, thereby inhibiting nerve impulse conduction and providing local anesthesia. The combination may be used for conditions where both smooth muscle relaxation (antispasmodic effect) and local anesthesia are desired—such as certain diagnostic procedures or pain management scenarios involving abdominal or pelvic organs. The specific indications for this exact combination are not widely documented in major formularies; however, both agents are well-established individually for their respective uses.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on hyoscine butyl bromide + lidocaine.